Clinical Pathway Modification Increases Adoption of Hypofractionated RT for Prostate Cancer

[unable to retrieve full-text content]

The prostate cancer CP was amended in January 2018 to make mHF-EBRT the recommended treatment for patients with low- and intermediate-risk …
Published at Fri, 18 Dec 2020 03:00:00 +0000